Hebei Changshan Biochem Pharma (300255) — Net Asset Quality Index
Hebei Changshan Biochem Pharma (300255) has a Net Asset Quality Index of 31.7% as of September 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥4.66 Billion minus total liabilities of CN¥3.18 Billion yields net assets of CN¥1.48 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Check Hebei Changshan Biochem Pharma asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Quality Index
Net Assets
Total Assets
Total Liabilities
Hebei Changshan Biochem Pharma Net Asset Quality Index Over Time (2008–2024)
This chart shows how Hebei Changshan Biochem Pharma's Net Asset Quality Index has evolved across 17 annual periods from 2008 to 2024. As of September 2025, the index stands at 31.7%, representing net assets of CN¥1.48 Billion against total assets of CN¥4.66 Billion CNY. See 300255 working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for Hebei Changshan Biochem Pharma (2008–2024)
The table below presents the year-by-year Net Asset Quality Index for Hebei Changshan Biochem Pharma from 2008 to 2024, covering 17 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see market cap of Hebei Changshan Biochem Pharma.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 34.0% | CN¥1.54 Billion | CN¥4.52 Billion | CN¥2.99 Billion | ▼ -5.2 pp |
| 2023 | 39.2% | CN¥1.80 Billion | CN¥4.60 Billion | CN¥2.80 Billion | ▼ -11.4 pp |
| 2022 | 50.6% | CN¥3.05 Billion | CN¥6.04 Billion | CN¥2.98 Billion | ▼ -8.6 pp |
| 2021 | 59.2% | CN¥3.07 Billion | CN¥5.19 Billion | CN¥2.12 Billion | ▼ -3.2 pp |
| 2020 | 62.4% | CN¥2.85 Billion | CN¥4.57 Billion | CN¥1.72 Billion | ▼ -6.6 pp |
| 2019 | 69.0% | CN¥2.72 Billion | CN¥3.94 Billion | CN¥1.22 Billion | ▲ +3.4 pp |
| 2018 | 65.6% | CN¥2.52 Billion | CN¥3.84 Billion | CN¥1.32 Billion | ▼ -3.4 pp |
| 2017 | 69.0% | CN¥2.44 Billion | CN¥3.53 Billion | CN¥1.09 Billion | ▼ -4.1 pp |
| 2016 | 73.1% | CN¥2.29 Billion | CN¥3.13 Billion | CN¥842.59 Million | ▲ +5.6 pp |
| 2015 | 67.5% | CN¥1.57 Billion | CN¥2.33 Billion | CN¥757.07 Million | ▼ -2.3 pp |
| 2014 | 69.8% | CN¥1.43 Billion | CN¥2.04 Billion | CN¥617.87 Million | ▼ -8.4 pp |
| 2013 | 78.1% | CN¥1.29 Billion | CN¥1.65 Billion | CN¥359.78 Million | ▼ -1.2 pp |
| 2012 | 79.4% | CN¥1.13 Billion | CN¥1.42 Billion | CN¥292.77 Million | ▼ -3.9 pp |
| 2011 | 83.2% | CN¥987.45 Million | CN¥1.19 Billion | CN¥198.78 Million | ▲ +32.3 pp |
| 2010 | 50.9% | CN¥219.39 Million | CN¥430.64 Million | CN¥211.25 Million | ▼ -8.8 pp |
| 2009 | 59.8% | CN¥159.19 Million | CN¥266.35 Million | CN¥107.15 Million | ▲ +12.2 pp |
| 2008 | 47.5% | CN¥93.43 Million | CN¥196.59 Million | CN¥103.16 Million | — |